DE1900367A1 - Stabile Glucagonloesung und Verfahren zu ihrer Herstellung - Google Patents

Stabile Glucagonloesung und Verfahren zu ihrer Herstellung

Info

Publication number: DE1900367A1
Authority: DE; Germany
Prior art keywords: glucagon; solution; months; detergent; solutions
Prior art date: 1968-01-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

DE19691900367

Other languages

German (de)

English (en)

Inventor

Jan Markussen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Terapeutisk Laboratorium AS

Original Assignee

Novo Terapeutisk Laboratorium AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1968-01-10

Filing date

1969-01-04

Publication date

1969-09-04

1969-01-04 Application filed by Novo Terapeutisk Laboratorium AS filed Critical Novo Terapeutisk Laboratorium AS

1969-09-04 Publication of DE1900367A1 publication Critical patent/DE1900367A1/de

Status Pending legal-status Critical Current

Links

102000051325 Glucagon Human genes 0.000 title claims description 83
108060003199 Glucagon Proteins 0.000 title claims description 83
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title claims description 83
229960004666 glucagon Drugs 0.000 title claims description 83
238000000034 method Methods 0.000 title description 6
238000002360 preparation method Methods 0.000 title description 2
239000003599 detergent Substances 0.000 claims description 35
229960003431 cetrimonium Drugs 0.000 claims description 17
RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 claims description 17
230000000087 stabilizing effect Effects 0.000 claims description 9
230000003381 solubilizing effect Effects 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 7
125000002091 cationic group Chemical group 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 5
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
150000008055 alkyl aryl sulfonates Chemical class 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
239000000243 solution Substances 0.000 description 116
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
239000013078 crystal Substances 0.000 description 15
238000003860 storage Methods 0.000 description 14
230000007935 neutral effect Effects 0.000 description 11
238000001556 precipitation Methods 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 7
238000001962 electrophoresis Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000004033 plastic Substances 0.000 description 5
229920003023 plastic Polymers 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229920001971 elastomer Polymers 0.000 description 4
239000000843 powder Substances 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000005189 flocculation Methods 0.000 description 3
230000016615 flocculation Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
125000001165 hydrophobic group Chemical group 0.000 description 3
239000000463 material Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000002002 slurry Substances 0.000 description 3
OBFSQMXGZIYMMN-UHFFFAOYSA-N 3-chloro-2-hexadecylpyridine Chemical compound CCCCCCCCCCCCCCCCC1=NC=CC=C1Cl OBFSQMXGZIYMMN-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 2
229960000228 cetalkonium chloride Drugs 0.000 description 2
230000009615 deamination Effects 0.000 description 2
238000006481 deamination reaction Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229940048957 glucagon 1 mg Drugs 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000003505 heat denaturation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940112041 peripherally acting muscle relaxants other quaternary ammonium compound in atc Drugs 0.000 description 1
-1 polyoxyethylene Polymers 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Detergent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE19691900367 1968-01-10 1969-01-04 Stabile Glucagonloesung und Verfahren zu ihrer Herstellung Pending DE1900367A1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB0536/68A GB1202607A (en)	1968-01-10	1968-01-10	Improvements in or relating to stable glucagon solutions and their preparation

Publications (1)

Publication Number	Publication Date
DE1900367A1 true DE1900367A1 (de)	1969-09-04

Family

ID=9723689

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE19691900367 Pending DE1900367A1 (de)	1968-01-10	1969-01-04	Stabile Glucagonloesung und Verfahren zu ihrer Herstellung

Country Status (7)

Country	Link
AT (1)	AT283600B (2)
BE (1)	BE726681A (2)
DE (1)	DE1900367A1 (2)
FR (1)	FR2000114A1 (2)
GB (1)	GB1202607A (2)
IT (1)	IT974528B (2)
NL (1)	NL6900460A (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995001185A1 (en) *	1993-06-29	1995-01-12	Ferring B.V.	Stabilized pharmaceutical peptide compositions

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
EP1061947B1 (en) *	1998-03-13	2004-06-16	Novo Nordisk A/S	Stabilized aqueous glucagon solutions comprising detergents
ATE269103T1 (de) *	1998-03-13	2004-07-15	Novo Nordisk As	Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
DK2490708T3 (da)	2009-10-22	2013-04-15	Biodel Inc	Stabiliserede glucagon-opløsninger
US9610329B2 (en)	2009-10-22	2017-04-04	Albireo Pharma, Inc.	Stabilized glucagon solutions
EP2635296B1 (en)	2010-11-03	2014-12-24	Arecor Limited	Novel composition comprising glucagon
BR112014016889A8 (pt)	2012-01-09	2017-07-04	Adocia	composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
US20150314003A2 (en)	2012-08-09	2015-11-05	Adocia	Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
AU2017277590A1 (en) *	2016-06-07	2019-01-24	Adocia	Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
FR3061660B1 (fr) *	2017-01-10	2019-05-31	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3052071B1 (fr) *	2016-06-07	2018-09-07	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide
GB201611077D0 (en)	2016-06-24	2016-08-10	Arecor Ltd	Novel composition
CA3084700A1 (en)	2017-12-07	2019-06-13	Adocia	Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
FR3074683B1 (fr) *	2017-12-07	2020-01-10	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
WO2019110838A1 (fr)	2017-12-07	2019-06-13	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
EP3731858A1 (fr)	2017-12-07	2020-11-04	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
MX2020005915A (es)	2017-12-07	2020-10-19	Adocia	Composiciones en forma de una solución acuosa inyectable que comprende glucagón humano y un copoliaminoácido.
FR3083087A1 (fr)	2018-06-29	2020-01-03	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3067247A1 (fr)	2018-06-07	2018-12-14	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2643967A (en) *	1946-08-31	1953-06-30	Wallerstein Co Inc	Concentrate of tyrothricin and its therapeutically active components
NL94376C (nl) *	1958-04-28	1960-05-16	Nv Organon	Werkwijze ter bereiding van injicieerbare glacagonpreparaten met verlengde werking

1968
- 1968-01-10 GB GB0536/68A patent/GB1202607A/en not_active Expired
1969
- 1969-01-04 DE DE19691900367 patent/DE1900367A1/de active Pending
- 1969-01-09 IT IT50089/69A patent/IT974528B/it active
- 1969-01-09 FR FR6900222A patent/FR2000114A1/fr not_active Withdrawn
- 1969-01-09 BE BE726681D patent/BE726681A/xx unknown
- 1969-01-10 NL NL6900460A patent/NL6900460A/xx unknown
- 1969-01-10 AT AT26769A patent/AT283600B/de not_active IP Right Cessation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995001185A1 (en) *	1993-06-29	1995-01-12	Ferring B.V.	Stabilized pharmaceutical peptide compositions
US5482931A (en) *	1993-06-29	1996-01-09	Ferring Ab	Stabilized pharmaceutical peptide compositions

Also Published As

Publication number	Publication date
IT974528B (it)	1974-07-10
GB1202607A (en)	1970-08-19
BE726681A (2)	1969-07-09
FR2000114A1 (fr)	1969-08-29
NL6900460A (2)	1969-07-14
AT283600B (de)	1970-08-10

Publication	Publication Date	Title
DE2036114C3 (de)	1979-09-13	Wäßriges Tetramisolpräparat
CH421076A (de)	1966-09-30	Verfahren zur Herstellung von Monobiguaniden
DE2324386C2 (de)	1975-07-03	Wäßriger Cholestrin-Standard
DE3000743C2 (de)	1985-07-11	Arzneipräparat auf der Basis eines Salzes der Acetylsalicylsäure und einer basischen Aminosäure
DE1045377C2 (de)	1959-05-27	Verfahren zum Stabilisieren von zur Herstellung von Fungiziden geeignetem Selendisulfid, das durch Zusatz eines hydrophilen kolloidalen Suspensionsmittels aktiviert ist
DE3112272C2 (2)	1990-09-27
EP0319598A1 (de)	1989-06-14	Stabilisierte wässrige Folsäurezubereitung
DE1470128A1 (de)	1969-05-29	Derivate von Vitamin K3
DE1467749A1 (de)	1968-12-05	Verfahren zur Herstellung von stabilen Tetracyclinpraeparaten
DE68902755T2 (de)	1993-01-14	Antineoplastische formulierungen.
DE69332039T2 (de)	2003-01-30	Hochkonzentrierte Aminosäurelösung
DE19540788A1 (de)	1997-05-07	Verwendung von wässrigen L-Tryptophan- und/oder L-Threonin-Salzlösungen
DE1911609C3 (de)	1975-10-16	Fotografische Fixiersalzmischung
DE964632C (de)	1957-05-23	Verfahren zur Herstellung farbbestaendiger, haltbarer Streptomycinloesungen hoher Wirksamkeit
DE689180C (de)	1940-03-13	Desinfektionsmittel
DE1692515C3 (de)	1974-06-06	Sulfachinoxalin enthaltende Zubereitungen
DE485052C (de)	1929-10-26	Gewinnung schwerloeslicher Fluoride in kolloidaler Form
DE1179378B (de)	1964-10-08	Verfahren zur Herstellung von wasserloeslichen, titrierbares Jod und als Traeger einPoly-[3-vinyl-5-methyloxazolidon-(2)] enthaltenden Kom-plexverbindungen
DE2036113A1 (de)	1971-02-04	Tetramisolpraparate
DE2521905A1 (de)	1975-12-04	Fumarsaeuresalz des 1-diaethylamino- aethyl-3-(p-methoxybenzyl)-1,2-dihydro- chinoxalin-2-ons, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel
DE2163062C3 (de)	1974-05-16	Mittel zum Frischhalten von Schnittblumen
DE3503206C2 (2)	1987-09-24
DE1767135B1 (de)	1971-10-07	Stabiles,festes D-Glucosaccharo-1,4-lacton oder dessen Salz enthaltendes Arzneimittel
DE1908078B1 (de)	1970-08-20	Biocide Zubereitung
DE287305C (2)